Corvus Pharmaceuticals held its 2026 Annual Meeting of Stockholders on June 11, 2026. A total of 73,021,854 shares were voted out of 84,090,424 shares outstanding as of the April 16, 2026 record date. Stockholders elected Richard A. Miller, M.D. and Linda S. Grais, M.D., J.D. as Class I directors. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2026 fiscal year. Stockholders approved the non-binding advisory vote on executive compensation.